OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Danilov on Addressing BTK Inhibitor Resistance in Relapsed/Refractory CLL and MCL

January 12th 2024

Alexey Danilov, MD, PhD, discusses how further research may address unmet needs in chronic lymphocytic leukemia or mantle cell lymphoma.

Dr Tantravahi on the Efficacy of Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

January 12th 2024

Srinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.

Dr Possik on the Importance of Diversity and Equity in Melanoma Research

January 11th 2024

Patricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.

Dr Grajales-Cruz on Real-World Responses With Teclistamab in Pretreated R/R Multiple Myeloma

January 11th 2024

Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes with teclistamab in select patients with relapsed/refractory multiple myeloma.

Dr Mascarenhas on the Potential Utility of Selinexor Plus Ruxolitinib in Myelofibrosis

January 11th 2024

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced/Metastatic ROS1+ NSCLC

January 11th 2024

Misako Nagasaka, MD, discusses key data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ non–small cell lung cancer.

Dr Meisel on AE Communication Challenges in Metastatic Breast Cancer Treatment

January 11th 2024

Jane L. Meisel, MD, shares data from a study on communication challenges between providers and patients with metastatic breast cancer regarding TRAEs.

Dr Rhodes on the Efficacy of Pirtobrutinib in Pretreated CLL/SLL

January 11th 2024

Joanna M. Rhodes, MD, MSCE, discusses the use of pirtobrutinib after covalent BTK inhibition in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Bezerra on the Real-World Efficacy of Brexu-Cel in B-ALL

January 11th 2024

Evandro D. Bezerra, MD, discusses real-world outcomes associated with brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in Hematology

January 11th 2024

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.

Dr Grivas on Key Data From the CheckMate 901 Trial in Urothelial Cancer

January 10th 2024

Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Dr Jain on the Impact of CD39+ T Cells on CAR T-Cell Phenotype

January 10th 2024

Michael Jain, MD, discusses the importance of evaluating the impact of lymphoma-associated CD39-positive T cells on CAR T-cell phenotypes.

Dr D'Abreo on Leveraging Biology When Treating HER2+ Breast Cancer

January 10th 2024

Nina D'Abreo, MD, discusses advances made in the treatment of patients with HER2-low and HER2-positive breast cancers.

Dr Wiestner on an Extended Follow-Up Study of Resistance Mutations With Acalabrutinib in CLL

January 10th 2024

Adrian Wiestner, MD, PhD, sheds light on resistance mutations in patients with chronic lymphocytic leukemia who were treated with acalabrutinib.

Dr Nowakowski on the Use of Emavusertib in Relapsed/Refractory Hematologic Malignancies

January 10th 2024

Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.

Dr Crafton on Emerging Therapeutic Targets in Ovarian Cancer

January 10th 2024

Sarah Crafton, MD, discusses novel therapeutic targets under investigation in patients with ovarian cancer.

Dr Bilusic on the Use of PARP Inhibitors in Prostate Cancer

January 10th 2024

Marijo Bilusic, MD, PhD, discusses key considerations and unanswered questions regarding the use of PARP inhibitors in patients with prostate cancer.

Dr In on the Importance of Early Cancer Prevention Strategies in Gastric Cancer

January 9th 2024

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.

Dr Baz on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple Myeloma

January 9th 2024

Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Giles on the Importance of Shared Decision Making When Managing GU Cancers

January 9th 2024

Rachel Giles, MD, PhD, discusses the importance of incorporating shared decision making in the treatment of patients with genitourinary cancers.